Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

During the Early Stages of Staphylococcus aureus Biofilm Formation, induced Neutrophil Extracellular Traps (NETs) are degraded by Autologous Thermonuclease.

Sultan AR, Hoppenbrouwers T, Lemmens-den Toom NA, Snijders SV, van Neck JW, Verbon A, de Maat MPM, van Wamel WJB.

Infect Immun. 2019 Sep 16. pii: IAI.00605-19. doi: 10.1128/IAI.00605-19. [Epub ahead of print]

PMID:
31527127
2.

Transforming growth factor-beta profiles correlate with clinical symptoms and parameters of haemostasis and inflammation in a controlled human malaria infection.

de Jong GM, McCall MBB, Dik WA, Urbanus RT, Wammes LJ, Koelewijn R, Sauerwein RW, Verbon A, van Hellemond JJ, van Genderen PJJ.

Cytokine. 2019 Sep 13;125:154838. doi: 10.1016/j.cyto.2019.154838. [Epub ahead of print]

PMID:
31525609
3.

Use of other antimicrobial drugs is associated with trimethoprim resistance in patients with urinary tract infections caused by E. coli.

Mulder M, Verbon A, Lous J, Goessens W, Stricker BH.

Eur J Clin Microbiol Infect Dis. 2019 Sep 7. doi: 10.1007/s10096-019-03672-2. [Epub ahead of print]

PMID:
31494829
4.

TOLLIP deficiency is associated with increased resistance to Legionella pneumophila pneumonia.

Shah JA, Emery R, Lee B, Venkatasubramanian S, Simmons JD, Brown M, Hung CF, Prins JM, Verbon A, Hawn TR, Skerrett SJ.

Mucosal Immunol. 2019 Aug 28. doi: 10.1038/s41385-019-0196-7. [Epub ahead of print]

PMID:
31462698
5.

Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period.

van Driel AA, Notermans DW, Meima A, Mulder M, Donker GA, Stobberingh EE, Verbon A.

Eur J Clin Microbiol Infect Dis. 2019 Aug 22. doi: 10.1007/s10096-019-03655-3. [Epub ahead of print]

PMID:
31440915
6.

Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy.

Wijting IE, Rokx C, Zillikens MC, Smits SA, de Vries-Sluijs TE, Schurink CA, Bax HI, van der Ende ME, van Gorp EC, Nouwen JL, Verbon A, Bierman WF, Rijnders BJ.

Int J STD AIDS. 2019 Aug 20:956462419848962. doi: 10.1177/0956462419848962. [Epub ahead of print] No abstract available.

PMID:
31431155
7.

Seasonality of antimicrobial resistance rates in respiratory bacteria: A systematic review and meta-analysis.

Martinez EP, Cepeda M, Jovanoska M, Bramer WM, Schoufour J, Glisic M, Verbon A, Franco OH.

PLoS One. 2019 Aug 15;14(8):e0221133. doi: 10.1371/journal.pone.0221133. eCollection 2019.

8.

Development of quality indicators for the management of Staphylococcus aureus bacteraemia.

Ten Oever J, Jansen JL, van der Vaart TW, Schouten JA, Hulscher MEJL, Verbon A.

J Antimicrob Chemother. 2019 Aug 8. pii: dkz342. doi: 10.1093/jac/dkz342. [Epub ahead of print]

PMID:
31393551
9.

Cervical cancer risk in women living with HIV across four continents: A multicohort study.

Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Paparizos V, Bonnet F, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J.

Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32260. [Epub ahead of print]

PMID:
31215037
10.

Trends of prescribing antimicrobial drugs for urinary tract infections in primary care in the Netherlands: a population-based cohort study.

Mulder M, Baan E, Verbon A, Stricker B, Verhamme K.

BMJ Open. 2019 May 19;9(5):e027221. doi: 10.1136/bmjopen-2018-027221.

11.

Anxiety, depression and treatment adherence among HIV-infected migrants.

Been SK, Schadé A, Bassant N, Kastelijns M, Pogány K, Verbon A.

AIDS Care. 2019 Aug;31(8):979-987. doi: 10.1080/09540121.2019.1601676. Epub 2019 Apr 8.

PMID:
30957530
12.

Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.

Popping S, Hullegie SJ, Boerekamps A, Rijnders BJA, de Knegt RJ, Rockstroh JK, Verbon A, Boucher CAB, Nichols BE, van de Vijver DAMC.

PLoS One. 2019 Jan 10;14(1):e0210179. doi: 10.1371/journal.pone.0210179. eCollection 2019.

13.

The effect of antimicrobial drug use on the composition of the genitourinary microbiota in an elderly population.

Mulder M, Radjabzadeh D, Hassing RJ, Heeringa J, Uitterlinden AG, Kraaij R, Stricker BH, Verbon A.

BMC Microbiol. 2019 Jan 9;19(1):9. doi: 10.1186/s12866-018-1379-1.

14.

Persistent metabolic changes in HIV-infected patients during the first year of combination antiretroviral therapy.

Peltenburg NC, Schoeman JC, Hou J, Mora F, Harms AC, Lowe SH, Bierau J, Bakker JA, Verbon A, Hankemeier T, Boonstra A.

Sci Rep. 2018 Nov 16;8(1):16947. doi: 10.1038/s41598-018-35271-0.

15.

T cell toxicity of HIV latency reversing agents.

Zhao M, De Crignis E, Rokx C, Verbon A, van Gelder T, Mahmoudi T, Katsikis PD, Mueller YM.

Pharmacol Res. 2019 Jan;139:524-534. doi: 10.1016/j.phrs.2018.10.023. Epub 2018 Oct 23.

PMID:
30366100
16.

Metabolic events in HIV-infected patients using abacavir are associated with erythrocyte inosine triphosphatase activity.

Peltenburg NC, Bierau J, Schippers JA, Lowe SH, Paulussen ADC, van den Bosch BJC, Leers MPG, Andrinopoulou ER, Bakker JA, Verbon A.

J Antimicrob Chemother. 2019 Jan 1;74(1):157-164. doi: 10.1093/jac/dky383.

PMID:
30304447
17.

Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.

Wijting I, Rutsaert SL, Rokx C, Burger DM, Verbon A, van Kampen J, Boucher C, Rijnders B, Vandekerckhove L.

HIV Med. 2019 Jan;20(1):63-68. doi: 10.1111/hiv.12675. Epub 2018 Sep 30.

18.

Persistent Replication of HIV, Hepatitis C Virus (HCV), and HBV Results in Distinct Gene Expression Profiles by Human NK Cells.

Boeijen LL, Hou J, de Groen RA, Verbon A, Boonstra A.

J Virol. 2019 Apr 17;93(9). pii: e00575-18. doi: 10.1128/JVI.00575-18. Print 2019 May 1.

PMID:
30185599
19.

Diet as a risk factor for antimicrobial resistance in community-acquired urinary tract infections in a middle-aged and elderly population: a case-control study.

Mulder M, Kiefte-de Jong JC, Goessens WHF, de Visser H, Ikram MA, Verbon A, Stricker BH.

Clin Microbiol Infect. 2019 May;25(5):613-619. doi: 10.1016/j.cmi.2018.07.029. Epub 2018 Aug 9.

PMID:
30099137
20.

Microbiology and antibiotic susceptibility patterns in spontaneous bacterial peritonitis: A study of two Dutch cohorts at a 10-year interval.

Oey RC, de Man RA, Erler NS, Verbon A, van Buuren HR.

United European Gastroenterol J. 2018 May;6(4):614-621. doi: 10.1177/2050640617744456. Epub 2017 Nov 20.

21.

Production of Staphylococcal Complement Inhibitor (SCIN) and Other Immune Modulators during the Early Stages of Staphylococcus aureus Biofilm Formation in a Mammalian Cell Culture Medium.

Sultan AR, Swierstra JW, Lemmens-den Toom NA, Snijders SV, Hansenová Maňásková S, Verbon A, van Wamel WJB.

Infect Immun. 2018 Jul 23;86(8). pii: e00352-18. doi: 10.1128/IAI.00352-18. Print 2018 Aug.

22.

A clinical decision support system algorithm for intravenous to oral antibiotic switch therapy: validity, clinical relevance and usefulness in a three-step evaluation study.

Akhloufi H, Hulscher M, van der Hoeven CP, Prins JM, van der Sijs H, Melles DC, Verbon A.

J Antimicrob Chemother. 2018 Aug 1;73(8):2201-2206. doi: 10.1093/jac/dky141.

PMID:
29718336
23.

The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.

Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Brüggemann RJ, Biemond BJ, Bart A, von dem Borne PA, Verbon A, van der Beek MT, Demandt AMP, Oudhuis GJ, Cornelissen JJ, van der Velden WJFM, Span LFR, Kampinga GA, Bruns AH, Vonk AG, Haas PA, Doorduijn JK, Rijnders BJA.

Mycoses. 2018 Sep;61(9):656-664. doi: 10.1111/myc.12788. Epub 2018 Jul 13.

PMID:
29687483
24.

Improving treatment outcome assessment in a mouse tuberculosis model.

Mourik BC, Svensson RJ, de Knegt GJ, Bax HI, Verbon A, Simonsson USH, de Steenwinkel JEM.

Sci Rep. 2018 Apr 9;8(1):5714. doi: 10.1038/s41598-018-24067-x.

25.

Development of diagnostic prediction tools for bacteraemia caused by third-generation cephalosporin-resistant enterobacteria in suspected bacterial infections: a nested case-control study.

Rottier WC, van Werkhoven CH, Bamberg YRP, Dorigo-Zetsma JW, van de Garde EM, van Hees BC, Kluytmans JAJW, Kuck EM, van der Linden PD, Prins JM, Thijsen SFT, Verbon A, Vlaminckx BJM, Ammerlaan HSM, Bonten MJM.

Clin Microbiol Infect. 2018 Dec;24(12):1315-1321. doi: 10.1016/j.cmi.2018.03.023. Epub 2018 Mar 23.

PMID:
29581056
26.

A multicentre verification study of the QuantiFERON®-TB Gold Plus assay.

Pieterman ED, Liqui Lung FG, Verbon A, Bax HI, Ang CW, Berkhout J, Blaauw G, Brandenburg A, van Burgel ND, Claessen A, van Dijk K, Heron M, Hooghiemstra M, Leussenkamp-Hummelink R, van Lochem E, van Loo IHM, Mulder B, Ott A, Pontesilli O, Reuwer A, Rombouts P, Saegeman V, Scholing M, Vainio S, de Steenwinkel JEM.

Tuberculosis (Edinb). 2018 Jan;108:136-142. doi: 10.1016/j.tube.2017.11.014. Epub 2017 Nov 28.

27.

Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV.

Peltenburg NC, Bierau J, Bakker JA, Schippers JA, Lowe SH, Paulussen ADC, van den Bosch BJC, Leers MPG, Hansen BE, Verbon A.

PLoS One. 2018 Jan 12;13(1):e0191069. doi: 10.1371/journal.pone.0191069. eCollection 2018.

28.

The common HAQ STING variant impairs cGAS-dependent antibacterial responses and is associated with susceptibility to Legionnaires' disease in humans.

Ruiz-Moreno JS, Hamann L, Shah JA, Verbon A, Mockenhaupt FP, Puzianowska-Kuznicka M, Naujoks J, Sander LE, Witzenrath M, Cambier JC, Suttorp N, Schumann RR, Jin L, Hawn TR, Opitz B; CAPNETZ Study Group.

PLoS Pathog. 2018 Jan 3;14(1):e1006829. doi: 10.1371/journal.ppat.1006829. eCollection 2018 Jan.

29.

Ending the epidemic: Critical role of primary HIV infection.

Prins HAB, Verbon A, Boucher CAB, Rokx C.

Neth J Med. 2017 Oct;75(8):321-327. Review.

30.

Non-targeted HIV screening in emergency departments in the Netherlands.

Luiken GPM, Joore IK, Taselaar A, Schuit SCE, Geerlings SE, Govers A, Rood PPM, Prins JM, Nichols BE, Verbon A, de Vries-Sluijs TEMS.

Neth J Med. 2017 Nov;75(9):386-393.

31.

Self-reported adherence and pharmacy refill adherence are both predictive for an undetectable viral load among HIV-infected migrants receiving cART.

Been SK, Yildiz E, Nieuwkerk PT, Pogány K, van de Vijver DAMC, Verbon A.

PLoS One. 2017 Nov 9;12(11):e0186912. doi: 10.1371/journal.pone.0186912. eCollection 2017.

32.

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.

Wijting I, Rokx C, Boucher C, van Kampen J, Pas S, de Vries-Sluijs T, Schurink C, Bax H, Derksen M, Andrinopoulou ER, van der Ende M, van Gorp E, Nouwen J, Verbon A, Bierman W, Rijnders B.

Lancet HIV. 2017 Dec;4(12):e547-e554. doi: 10.1016/S2352-3018(17)30152-2. Epub 2017 Oct 26.

PMID:
29107562
33.

Mucosal-associated invariant T-cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis.

Beudeker BJB, van Oord GW, Arends JE, Schulze Zur Wiesch J, van der Heide MS, de Knegt RJ, Verbon A, Boonstra A, Claassen MAA.

Liver Int. 2018 Mar;38(3):458-468. doi: 10.1111/liv.13544. Epub 2017 Sep 16.

34.

Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.

Mourik BC, de Knegt GJ, Verbon A, Mouton JW, Bax HI, de Steenwinkel JEM.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00696-17. doi: 10.1128/AAC.00696-17. Print 2017 Oct.

35.

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.

Bax HI, Bakker-Woudenberg IAJM, de Vogel CP, van der Meijden A, Verbon A, de Steenwinkel JEM.

Tuberculosis (Edinb). 2017 Jul;105:80-85. doi: 10.1016/j.tube.2017.04.010. Epub 2017 Apr 27.

PMID:
28610791
36.

Development of operationalized intravenous to oral antibiotic switch criteria.

Akhloufi H, Hulscher M, Melles DC, Prins JM, van der Sijs H, Verbon A.

J Antimicrob Chemother. 2017 Feb;72(2):543-546. doi: 10.1093/jac/dkw470. Epub 2016 Dec 20.

PMID:
27999021
37.

Systematic review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets?

de Jong GM, Slager JJ, Verbon A, van Hellemond JJ, van Genderen PJ.

Malar J. 2016 Dec 1;15(1):581. Review.

38.

Inosine Triphosphate Pyrophosphohydrolase Expression: Decreased in Leukocytes of HIV-Infected Patients Using Combination Antiretroviral Therapy.

Peltenburg NC, Leers MP, Bakker JA, Lowe SH, Vroemen WH, Paulussen AD, van den Bosch BJ, Bierau J, Verbon A.

J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):390-395.

PMID:
27792682
39.

Risk Factors for Non-Adherence to cART in Immigrants with HIV Living in the Netherlands: Results from the ROtterdam ADherence (ROAD) Project.

Been SK, van de Vijver DA, Nieuwkerk PT, Brito I, Stutterheim SE, Bos AE, Wolfers ME, Pogány K, Verbon A.

PLoS One. 2016 Oct 5;11(10):e0162800. doi: 10.1371/journal.pone.0162800. eCollection 2016.

40.

Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population.

Mulder M, Kiefte-de Jong JC, Goessens WH, de Visser H, Hofman A, Stricker BH, Verbon A.

J Antimicrob Chemother. 2017 Jan;72(1):281-289. Epub 2016 Sep 21.

PMID:
27655855
41.
42.

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.

Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord, Rohner E, Schmidlin K, Zwahlen M, Chakraborty R, Clifford G, Obel N, Grabar S, Verbon A, Noguera-Julian A, Collins IJ, Rojo P, Brockmeyer N, Campbell M, Chêne G, Prozesky H, Eley B, Stefan DC, Davidson A, Chimbetete C, Sawry S, Davies MA, Kariminia A, Vibol U, Sohn A, Egger M, Bohlius J.

Clin Infect Dis. 2016 Nov 1;63(9):1245-1253. Epub 2016 Aug 30.

43.

Detection of amino acid substitutions in the GyrA protein of fluoroquinolone-resistant typhoidal Salmonella isolates using high-resolution mass spectrometry.

Hassing RJ, Goessens WH, Zeneyedpour L, Sultan S, van Kampen JJ, Verbon A, van Genderen PJ, Hays JP, Luider TM, Dekker LJ.

Int J Antimicrob Agents. 2016 May;47(5):351-6. doi: 10.1016/j.ijantimicag.2016.01.018. Epub 2016 Mar 15.

PMID:
27132191
44.

Proton pump inhibitors and gastroenteritis.

Hassing RJ, Verbon A, de Visser H, Hofman A, Stricker BH.

Eur J Epidemiol. 2016 Oct;31(10):1057-1063. Epub 2016 Mar 10.

45.

Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro.

Bax HI, Bakker-Woudenberg IA, Ten Kate MT, Verbon A, de Steenwinkel JE.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2577-9. doi: 10.1128/AAC.02864-15. Print 2016 Apr.

46.

Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.

Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, Kan TW, Boucher C, Verbon A, Dykhuizen EC, Mahmoudi T.

EBioMedicine. 2015 Nov 27;3:108-121. doi: 10.1016/j.ebiom.2015.11.047. eCollection 2016 Jan.

47.

Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.

Rokx C, Gras L, van de Vijver D, Verbon A, Rijnders B; ATHENA National Observational Cohort Study.

HIV Med. 2016 Sep;17(8):571-80. doi: 10.1111/hiv.12355. Epub 2016 Feb 4.

48.

TB-HIV co-infection in the Netherlands: estimating prevalence and under-reporting in national registration databases using a capture-recapture analysis.

van Leth F, Evenblij K, Wit F, Kiers A, Sprenger H, Verhagen M, Hillebregt M, Kalisvaart N, Schimmel H, Verbon A.

J Epidemiol Community Health. 2016 Jun;70(6):556-60. doi: 10.1136/jech-2015-206680. Epub 2015 Dec 23.

PMID:
26700301
49.

International travel and acquisition of multidrug-resistant Enterobacteriaceae: a systematic review.

Hassing RJ, Alsma J, Arcilla MS, van Genderen PJ, Stricker BH, Verbon A.

Euro Surveill. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30074. Review.

50.

Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study.

Nichols BE, Götz HM, van Gorp EC, Verbon A, Rokx C, Boucher CA, van de Vijver DA.

PLoS One. 2015 Nov 10;10(11):e0142576. doi: 10.1371/journal.pone.0142576. eCollection 2015.

Supplemental Content

Loading ...
Support Center